Annual report of publications in <i>Epilepsia</i> in 2024, the official journal of the International League Against Epilepsy_Journal of Epilepsy

Authors：

HU Xiaowei ¹ , XU Min ¹ , CHENG Qingzhang ² , TANG Jihong ³ , SHAO Guofu ⁴ , LIU Jiannong ⁵ ,  LI Yan ³

1. Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China;
2. Department of Neurology, Suzhou Hospital, Nanjing Medical University, Suzhou 215006, China;
3. Department of Neurology, Children's Hospital of Soochow University, Suzhou 215006, China;
4. Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou 215006, China;
5. Department of Neurology, Suzhou Guangji Hospital, Suzhou 215006, China;

Corresponding author：

LI Yan, Email: yan62bh@126.com

Keywords：

Epilepsia; Journal; Annual report; Review

DOI：

10.7507/2096-0247.202504006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Epilepsia is the official journal of the International League Against Epilepsy. This paper aimed to review and report the literatures published in 2024. A total of 348 articles were published in the journal Epilepsia in 2024, including 6 editorials, 41 critical reviews (systematic reviews and meta-analyses), 11 commentaries, 223 research articles, 31 brief communications, 30 others (including announcements, correspondences and corrections), and 6 special reports. Epilepsia is a journal focusing on epilepsy in clinical neurology, and the literatures published in 2024 are still dominated by clinical studies, although the number of randomized controlled trials is limitted. Chinese authors have published 10 original studies, some of which are important studies, and have contributed Chinese wisdom to the clinical and scientific research of epilepsy. In 2024, the editorials of Epilepsia reported first editor-in-chief in history from outside the USA and Europe, who advocated for strengthening cooperation with epilepsy organizations and associations around the world, promoting the continuous development and progress of Epilepsia.

1.	Epilepsia [EB/OL]. [2025-01-20]. https://onlinelibrary.wiley.com/journal/15281167.
2.	Sperling MR. Farewell from the editor-in-chief. Epilepsia, 2024, 65(8): 2183-2184.
3.	Valente KD, Reilly C, Carvalho RM, et al. Consensus-based recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy: a report from the Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy. Epilepsia, 2024, 65(11): 3155-3185.
4.	Elamin M, Lemtiri-Chlieh F, Robinson TM, et al. Dysfunctional sodium channel kinetics as a novel epilepsy mechanism in chromosome 15q11-q13 duplication syndrome. Epilepsia, 2023, 64(9): 2515-2527.
5.	Sperling MR. An interview with Marwa Elamin, 2024 Epilepsia prize winner for basic science research. Epilepsia, 2024, 65(8): 2499-2500.
6.	Wissel BD, Greiner HM, Glauser TA, et al. Automated, machine learning-based alerts increase epilepsy surgery referrals: a randomized controlled trial. Epilepsia, 2023, 64(7): 1791-1799.
7.	Sperling MR. An interview with Benjamin D. Wissel, 2024 Epilepsia Prize winner for clinical research. Epilepsia, 2024, 65(8): 2497-2498.
8.	Cerulli Irelli E, Borioni MS, Morano A, et al. Frailty as a comprehensive health measure beyond seizure control in patients with epilepsy: a cross-sectional study. Epilepsia, 2024, 65(6): 1658-1667.
9.	Bosque Varela P, Tabaee Damavandi P, Machegger L, et al. Magnetic resonance imaging fingerprints of status epilepticus: a case-control study. Epilepsia, 2024, 65(6): 1620-1630.
10.	Roberti R, Di Gennaro G, Anzellotti F, et al. A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. Epilepsia, 2024, 65(2): 456-472.
11.	Singh R, Troelstrup D, Dahl N. Safety and tolerability of intravenous undiluted levetiracetam in pediatrics: a retrospective cohort study. Epilepsia, 2024, 65(12): e204-e208.
12.	Cai L, Li G, Abdulaziz AT, et al. Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: a multicenter prospective cohort study. Epilepsia, 2024, 65(11): 3199-3215.
13.	Tantillo GB, Dongarwar D, Venkatasubba Rao CP, et al. Health care disparities in morbidity and mortality in adults with acute and remote status epilepticus: a national study. Epilepsia, 2024, 65(6): 1589-1604.
14.	Tantillo GB, Sullivan-Baca E, Rehman R, et al. Health care utilization of Hispanic/Latino veterans with epilepsy: a national population-based study. Epilepsia, 2024, 65(6): 1668-1678.
15.	Chassoux F, Navarro V, Quirins M, et al. Vitamin D deficiency and effect of treatment on seizure frequency and quality of life parameters in patients with drug-resistant epilepsy: a randomized clinical trial. Epilepsia, 2024, 65(9): 2612-2625.
16.	Perucca P, Bourikas D, Voinescu PE, et al. Lacosamide and pregnancy: data from spontaneous and solicited reports. Epilepsia, 2024, 65(5): 1275-1284.
17.	Vossler DG, Farkas MK, Poverennova I, et al. Long-term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic-clonic seizures: an open-label extension trial. Epilepsia, 2024, 65(12): 3488-3500.
18.	Novitskaya Y, Schutz E, Metternich B, et al. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia, 2024, 65(3): 630-640.
19.	Roberti R, Assenza G, Bisulli F, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia, 2024, 65(10): 2909-2922.
20.	Ferrari L, Rosenfeld WE, Kamin M. A global update on cenobamate based on real-world experience in over 100 000 patients. Epilepsia, 2024, 65(4): 1149-1150.
21.	Glatt S, Shohat S, Yam M, et al. Cannabidiol-enriched oil for adult patients with drug-resistant epilepsy: prospective clinical and electrophysiological study. Epilepsia, 2024, 65(8): 2270-2279.
22.	Pietrafusa N, Trivisano M, Casellato S, et al. Fenfluramine below the age of 2 years in Dravet syndrome: what about safety and efficacy? Epilepsia, 2024, 65(2): e7-e13.
23.	Hu X, Gao W, Xu M, et al. Publications from China in epilepsia. Epilepsia, 2013, 54(11): 1851.
24.	Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
25.	Fu Y, Shi F, Sha L, et al. Effects of antiseizure medication withdrawal during the first trimester of pregnancy on seizure control and offspring outcomes. Epilepsia, 2024, 65(11): 3186-3198.
26.	Tong X, Wang Q, Yang J, et al. Optimizing ketogenic diet therapy for childhood epilepsy: identifying key factors for seizure control and psychomotor enhancement. Epilepsia, 2024, 65(10): 2959-2972.
27.	Zhong R, Li G, Zhao T, et al. Association of baseline sleep duration and sleep quality with seizure recurrence in newly treated patients with epilepsy. Epilepsia, 2024, 65(11): 3224-3233.
28.	Fu Y, Zhang J, Cao Y, et al. Recognition memory deficits detected through eye-tracking in well-controlled children with self-limited epilepsy with centrotemporal spikes. Epilepsia, 2024, 65(4): 1128-1140.
29.	Zhou C, Xie F, Wang D, et al. Preoperative structural-functional coupling at the default mode network predicts surgical outcomes of temporal lobe epilepsy. Epilepsia, 2024, 65(4): 1115-1127.
30.	Sun Y, Ku MY, Liu CC, et al. Characteristics of motor vehicle crashes and fatality risk among drivers with epilepsy. Epilepsia, 2024, 65(10): 2984-2994.
31.	Wang H, Qiao Z, Luan K, et al. Identification of a new retigabine derivative with improved photostability for selective activation of neuronal Kv7 channels and antiseizure activity. Epilepsia, 2024, 65(10): 2923-2934.
32.	Ge J, Xie S, Duan J, et al. Imbalance between hippocampal projection cell and parvalbumin interneuron architecture increases epileptic susceptibility in mouse model of methyl CpG binding protein 2 duplication syndrome. Epilepsia, 2024, 65(8): 2483-2496.
33.	Cross HJ. Thank you to the outgoing editor-in-chief of Epilepsia, Michael Sperling. Epilepsia, 2024, 65(8): 2185.
34.	Cendes F. Introduction of the incoming editor-in-chief of Epilepsia. Epilepsia, 2024, 65(9): 2505-2505.

1. Epilepsia [EB/OL]. [2025-01-20]. https://onlinelibrary.wiley.com/journal/15281167.
2. Sperling MR. Farewell from the editor-in-chief. Epilepsia, 2024, 65(8): 2183-2184.
3. Valente KD, Reilly C, Carvalho RM, et al. Consensus-based recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy: a report from the Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy. Epilepsia, 2024, 65(11): 3155-3185.
4. Elamin M, Lemtiri-Chlieh F, Robinson TM, et al. Dysfunctional sodium channel kinetics as a novel epilepsy mechanism in chromosome 15q11-q13 duplication syndrome. Epilepsia, 2023, 64(9): 2515-2527.
5. Sperling MR. An interview with Marwa Elamin, 2024 Epilepsia prize winner for basic science research. Epilepsia, 2024, 65(8): 2499-2500.
6. Wissel BD, Greiner HM, Glauser TA, et al. Automated, machine learning-based alerts increase epilepsy surgery referrals: a randomized controlled trial. Epilepsia, 2023, 64(7): 1791-1799.
7. Sperling MR. An interview with Benjamin D. Wissel, 2024 Epilepsia Prize winner for clinical research. Epilepsia, 2024, 65(8): 2497-2498.
8. Cerulli Irelli E, Borioni MS, Morano A, et al. Frailty as a comprehensive health measure beyond seizure control in patients with epilepsy: a cross-sectional study. Epilepsia, 2024, 65(6): 1658-1667.
9. Bosque Varela P, Tabaee Damavandi P, Machegger L, et al. Magnetic resonance imaging fingerprints of status epilepticus: a case-control study. Epilepsia, 2024, 65(6): 1620-1630.
10. Roberti R, Di Gennaro G, Anzellotti F, et al. A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. Epilepsia, 2024, 65(2): 456-472.
11. Singh R, Troelstrup D, Dahl N. Safety and tolerability of intravenous undiluted levetiracetam in pediatrics: a retrospective cohort study. Epilepsia, 2024, 65(12): e204-e208.
12. Cai L, Li G, Abdulaziz AT, et al. Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: a multicenter prospective cohort study. Epilepsia, 2024, 65(11): 3199-3215.
13. Tantillo GB, Dongarwar D, Venkatasubba Rao CP, et al. Health care disparities in morbidity and mortality in adults with acute and remote status epilepticus: a national study. Epilepsia, 2024, 65(6): 1589-1604.
14. Tantillo GB, Sullivan-Baca E, Rehman R, et al. Health care utilization of Hispanic/Latino veterans with epilepsy: a national population-based study. Epilepsia, 2024, 65(6): 1668-1678.
15. Chassoux F, Navarro V, Quirins M, et al. Vitamin D deficiency and effect of treatment on seizure frequency and quality of life parameters in patients with drug-resistant epilepsy: a randomized clinical trial. Epilepsia, 2024, 65(9): 2612-2625.
16. Perucca P, Bourikas D, Voinescu PE, et al. Lacosamide and pregnancy: data from spontaneous and solicited reports. Epilepsia, 2024, 65(5): 1275-1284.
17. Vossler DG, Farkas MK, Poverennova I, et al. Long-term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic-clonic seizures: an open-label extension trial. Epilepsia, 2024, 65(12): 3488-3500.
18. Novitskaya Y, Schutz E, Metternich B, et al. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia, 2024, 65(3): 630-640.
19. Roberti R, Assenza G, Bisulli F, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia, 2024, 65(10): 2909-2922.
20. Ferrari L, Rosenfeld WE, Kamin M. A global update on cenobamate based on real-world experience in over 100 000 patients. Epilepsia, 2024, 65(4): 1149-1150.
21. Glatt S, Shohat S, Yam M, et al. Cannabidiol-enriched oil for adult patients with drug-resistant epilepsy: prospective clinical and electrophysiological study. Epilepsia, 2024, 65(8): 2270-2279.
22. Pietrafusa N, Trivisano M, Casellato S, et al. Fenfluramine below the age of 2 years in Dravet syndrome: what about safety and efficacy? Epilepsia, 2024, 65(2): e7-e13.
23. Hu X, Gao W, Xu M, et al. Publications from China in epilepsia. Epilepsia, 2013, 54(11): 1851.
24. Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
25. Fu Y, Shi F, Sha L, et al. Effects of antiseizure medication withdrawal during the first trimester of pregnancy on seizure control and offspring outcomes. Epilepsia, 2024, 65(11): 3186-3198.
26. Tong X, Wang Q, Yang J, et al. Optimizing ketogenic diet therapy for childhood epilepsy: identifying key factors for seizure control and psychomotor enhancement. Epilepsia, 2024, 65(10): 2959-2972.
27. Zhong R, Li G, Zhao T, et al. Association of baseline sleep duration and sleep quality with seizure recurrence in newly treated patients with epilepsy. Epilepsia, 2024, 65(11): 3224-3233.
28. Fu Y, Zhang J, Cao Y, et al. Recognition memory deficits detected through eye-tracking in well-controlled children with self-limited epilepsy with centrotemporal spikes. Epilepsia, 2024, 65(4): 1128-1140.
29. Zhou C, Xie F, Wang D, et al. Preoperative structural-functional coupling at the default mode network predicts surgical outcomes of temporal lobe epilepsy. Epilepsia, 2024, 65(4): 1115-1127.
30. Sun Y, Ku MY, Liu CC, et al. Characteristics of motor vehicle crashes and fatality risk among drivers with epilepsy. Epilepsia, 2024, 65(10): 2984-2994.
31. Wang H, Qiao Z, Luan K, et al. Identification of a new retigabine derivative with improved photostability for selective activation of neuronal Kv7 channels and antiseizure activity. Epilepsia, 2024, 65(10): 2923-2934.
32. Ge J, Xie S, Duan J, et al. Imbalance between hippocampal projection cell and parvalbumin interneuron architecture increases epileptic susceptibility in mouse model of methyl CpG binding protein 2 duplication syndrome. Epilepsia, 2024, 65(8): 2483-2496.
33. Cross HJ. Thank you to the outgoing editor-in-chief of Epilepsia, Michael Sperling. Epilepsia, 2024, 65(8): 2185.
34. Cendes F. Introduction of the incoming editor-in-chief of Epilepsia. Epilepsia, 2024, 65(9): 2505-2505.

Journal of Epilepsy

Latest ArticlesAnnual report of publications in Epilepsia in 2024, the official journal of the International League Against Epilepsy

Abstract Full text Figures/Tables Video References Cited by

Format

Content